title: Do we really need new trials on fulvestrant in prostate cancer?
authors.forename: Aude
authors.initials: A
authors.lastname: Féchon
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Droz
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002369:Castration; D003131:Combined Modality Therapy; D018450:Disease Progression; D004334:Drug Administration Schedule; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077267:Fulvestrant; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000077267:Fulvestrant; D004958:Estradiol; D017430:Prostate-Specific Antigen